Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Report 2023

Report ID: 857568 | Published Date: Jan 2025 | No. of Page: 147 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.

Market Analysis and Insights: Global Recombinant Human Granulocyte Colony-Stimulating Market
The global Recombinant Human Granulocyte Colony-Stimulating market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Recombinant Human Granulocyte Colony-Stimulating Scope and Market Size
The global Recombinant Human Granulocyte Colony-Stimulating market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Granulocyte Colony-Stimulating market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Others

Segment by Application
Chemotherapy Induced Neutropenia
Before Blood Donation
Stem Cell Transplants
Others

The Recombinant Human Granulocyte Colony-Stimulating market is analysed and market size information is provided by regions (countries). Segment by Application, the Recombinant Human Granulocyte Colony-Stimulating market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Amgen
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Kyowa Hakko Kirin
Gensci
Amoytop Biotech
Hangzhou Jiuyuan
Huaxin
Triprime
Sinovac
Zhaoke
Kawin

Frequently Asked Questions
Recombinant Human Granulocyte Colony-Stimulating report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Recombinant Human Granulocyte Colony-Stimulating report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Recombinant Human Granulocyte Colony-Stimulating report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports